[ad_1]
The biotech company Moderna has shared the findings that its coronavirus vaccine offered immunity to trial participants for up to three months after the second puncture.
The vaccine is still awaiting emergency approval from the US Food and Drug Administration (FDA), which plans to meet on December 17 to discuss the company’s application. The FDA will meet on December 10 to discuss the Pfizer vaccine. Meanwhile, state leaders and health officials have begun announcing that initial doses of coronavirus vaccines, namely from Pfizer, are expected in the coming weeks pending FDA approval.
HOW DO MODERN AND PFIZER CORONAVIRUS VACCINES COMPARE?
A team of physicians involved in the Moderna vaccine clinical trial published a correspondence in the New England Journal of Medicine Thursday, detailing the findings among 34 healthy adult participants.
The jab involves a two-dose regimen, administered 28 days apart. At the 100 microgram (μg) dose, the vaccine “produced high levels of neutralizing and binding antibodies that decreased slightly over time, as expected, but remained elevated in all participants 3 months after the booster dose. [second] vaccination, ”the doctors wrote. Antibody levels among trial participants also “exceeded” those of 41 recovering COVID-19 patients in a control group.
Adults ages 18 to 55 saw the highest levels of antibodies, followed by the oldest participants (over 71 years of age), and finally those ages 56 to 70. The team reported no serious adverse events “nor new adverse events that were considered by the investigators to be related to the vaccine occurred after day 57.”
UK DEFENDS PFIZER CORONAVIRUS VACCINE DECISION AMID CRITICS MOVES TOO FAST
The researchers say it is “not yet established” whether the antibodies translate into protection against SARS-CoV-2 infection, but the results imply that the vaccine has the potential to offer “long-lasting immunity” against the disease.
“Our findings support the use of a 100 µg dose of mRNA-1273 in an ongoing phase 3 trial, which has recently shown an efficacy rate of 94.5% in an interim analysis,” the researchers concluded.
GET THE FOX NEWS APP
